Key result
LMWH remains the preferred anticoagulant for managing VTE during pregnancy.
Design
Review
Authors
Loading...
Affirms LMWH preference for pregnancy-associated VTE; leaves open need for RCTs on alternatives.
Provides a clinical overview of the diagnosis, screening, and management of venous thromboembolism during pregnancy, highlighting low-molecular-weight heparin as the preferred treatment.
Dresang et al. (2023) conducted a review in Venous Thromboembolism in Pregnancy. Low-molecular-weight heparin (LMWH) was evaluated. Venous thromboembolism is a major cause of maternal mortality during pregnancy, and low-molecular-weight heparin remains the preferred anticoagulant therapy for its management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: